Related Experiment Video
Updated: Sep 15, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review.
Kyle A Grenier1, Carly S Sanderson, Giuliano Paoletta
1University of Connecticut School of Pharmacy, Storrs, CT (KAG, CSS, GP, KKA).
Low-dose buprenorphine initiation (LDBI) in pregnant patients showed uncommon precipitated withdrawal. Some withdrawal symptoms were frequent, but more research is needed to confirm findings.
Area of Science:
- Obstetrics and Gynecology
- Addiction Medicine
- Pharmacology
Background:
- Traditional buprenorphine initiation requires opioid withdrawal.
- Low-dose buprenorphine initiation (LDBI) was developed to avoid this prerequisite.
- LDBI is increasingly used for opioid use disorder treatment in pregnant individuals.
Purpose of the Study:
- To determine the rates of withdrawal in pregnant patients transitioning to buprenorphine using LDBI.
- To assess the safety and tolerability of LDBI in this population.
Main Methods:
- Systematic literature review of Embase, MEDLINE, Scopus, Google, Google Scholar, and clinicaltrials.gov.
- Inclusion of observational studies evaluating LDBI in pregnant patients.
- Extraction of patient data and synthesis of withdrawal outcomes.
Main Results:
- Seven observational studies with 25 unique patients were included.
- Precipitated withdrawal occurred in 8% of patients.
- 32% of patients experienced mild to moderate withdrawal, though reporting was inconsistent.
Conclusions:
- Emerging evidence suggests LDBI is feasible in pregnant patients.
- While some withdrawal is common, precipitated withdrawal is infrequent.
- Further high-quality research, including randomized controlled trials, is necessary to confirm these findings and address potential biases.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Factors Affecting Drug Response: Overview
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Analgesia and Pain Management
Drug Dependence

